Within the statistical testing hierarchy, eptinezumab 30 mg did not achieve significance for any of the prespecified primary and key secondary endpoints; thus, formal statistical testing of the remaining endpoints was not performed (for more information, please see Supplemental material 3).
← all excerpts
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
1
—
—